Can One Blood Test Detect 50 Cancers Early?
The Galleri MCED Test — New Evidence Reviewed

The promise of a single blood test that could detect more than 50 types of cancer before symptoms appear sounds almost too good to be true. For several years, the Galleri test — a multicancer early detection (MCED) test developed by GRAIL — has been generating that level of anticipation. Now, three major datasets have reported results. The data are instructive, nuanced, and important to read carefully.

Here is what the evidence actually shows.

How the Test Works

The Galleri test is a liquid biopsy that analyses circulating tumour DNA (ctDNA) shed by cancer cells into the bloodstream. Its distinguishing feature is not simply detecting ctDNA — many tests do that — but analysing DNA methylation patterns: chemical modifications to DNA that differ systematically between cancer cells and normal cells, and that vary in characteristic ways between different tumour types.

This methylation signature analysis allows the test to do two things from a single blood draw: detect whether a cancer signal is present at all, and if so, predict the likely tissue of origin — guiding clinicians toward the right follow-up investigation rather than requiring a pan-body imaging search. The test covers more than 50 cancer types, including several — ovarian, pancreatic, hepatocellular — for which no established population screening protocols currently exist.

Three Datasets — What They Show

NHS-Galleri Trial

The NHS-Galleri randomised controlled trial enrolled more than 140,000 participants across England. It is the largest RCT of an MCED test to date, and its design — randomising participants to receive Galleri screening or standard care — represents the gold standard for evaluating a screening intervention.

The primary outcome was a reduction in the incidence of stage III and IV (advanced) cancer diagnoses. This endpoint was not met — the difference between arms was not statistically significant. However, the trial did show a meaningful increase in early-stage cancer diagnoses in the intervention arm, and importantly, a reduction in emergency cancer presentations — cases where cancer is first diagnosed at an emergency department visit, a setting associated with very poor outcomes.

The absence of a significant result on the primary endpoint does not render the test ineffective, but it does mean the most stringent standard of evidence — demonstrating that the test actually prevents late-stage disease at the population level — has not yet been achieved. Longer follow-up may reveal a different picture.

SYMPLIFY Study

The SYMPLIFY study took a different approach: it tested Galleri alongside standard diagnostic workup in 5,461 symptomatic patients referred through the urgent cancer pathway in England and Wales. This is a higher-prevalence population than asymptomatic screening participants, which affects the interpretation of sensitivity and specificity figures.

In this symptomatic cohort, Galleri showed:

• Sensitivity: 66.3% — correctly identified approximately two-thirds of confirmed cancer cases
• Specificity: 98.4% — very few false positives in non-cancer patients
• Tumour origin accuracy: 85.2% — among those with a detected cancer signal, the predicted site of origin was correct in 85% of cases

The SYMPLIFY data also showed that accuracy varied significantly depending on symptom clustering and referral route — reinforcing that clinical context matters for interpreting results.

The Critical Number: Sensitivity by Stage

Perhaps the most important data for understanding the test's real-world utility comes from validation studies in asymptomatic individuals — the population most relevant to cancer screening. Overall sensitivity in this group is 51.5%. But the breakdown by stage is what demands attention:

This pattern — high sensitivity at late stages, low sensitivity at early stages — is a fundamental challenge for any test that detects cancer via shed DNA. Early-stage tumours shed less DNA into the circulation, making them harder to detect by any liquid biopsy approach. It is not a flaw in this specific test; it is a biological constraint of the technology.

Understanding Positive Predictive Value

The Galleri test has high specificity — greater than 99% in validation studies, meaning false positive rates are very low. But specificity and positive predictive value (PPV) are different things, and in low-prevalence screening populations, even a highly specific test can generate a meaningful proportion of false positives.

Published studies report a PPV of 43–75% for Galleri. This means that between one-quarter and more than half of positive results may not correspond to a confirmed cancer diagnosis after full workup. Every positive result requires follow-up — imaging, endoscopy, or biopsy — which carries cost, delay, procedural risk, and significant psychological burden for the patient.

The Unanswered Question: Does It Save Lives?

The most important question in cancer screening is not "does the test find cancer?" but "does finding cancer this way reduce the risk of dying from it?" These are not the same question.

Early detection can shift a cancer from a later to an earlier stage classification without actually extending life — if the cancer was always going to behave the same way, or if it is a slow-growing tumour that would never have caused harm. These biases (lead-time bias and length-time bias) affect all screening tests, and they are why survival data alone is not sufficient to demonstrate screening benefit.

To date, no study has demonstrated that the Galleri test reduces cancer mortality. The NHS-Galleri trial will provide mortality data on longer follow-up. Until those data are available, the mortality question remains open — and it is the question that regulators, health systems, and cost-effectiveness analyses will ultimately require an answer to.

Availability and Access

The test is currently available in the United States at a cost of approximately USD 949 (as of 2026), available by physician prescription without insurance coverage for most patients. It is not yet covered by Medicare or most private insurers, limiting access largely to those who can pay out of pocket.

In Brazil, the test is expected to become available by the end of 2026, initially through private clinics and by physician prescription. As of July 2026, it has not yet received official registration or approval from ANVISA (Brazil's National Health Surveillance Agency), which means it is in a regulatory pre-approval phase. Its incorporation into Brazil's public health system will depend on cost-effectiveness studies and mortality outcome data — both of which remain pending.

The Bottom Line

The Galleri test is a genuine scientific advance. The technology — methylation-based multicancer detection from a single blood draw — is novel, and the clinical studies are large and well-designed. Some of the results are encouraging: high specificity, strong tumour origin accuracy in symptomatic patients, and a real-world detection signal in a large deployment dataset.

But the evidence also contains important cautions. Stage I sensitivity of 16.8% is a meaningful limitation for a screening tool in asymptomatic populations. The primary endpoint of the NHS-Galleri RCT was not met. Mortality benefit has not been demonstrated. And the moderate PPV means that positive results reliably generate a follow-up workup burden — which may or may not lead to a cancer diagnosis.

The test should be understood for what it is: a complement to existing screening — not a replacement for mammography, colonoscopy, or PSA testing — and particularly valuable in populations at risk for cancer types with no current early detection option. Its ultimate role in clinical practice and public health will be determined by the mortality data and cost-effectiveness analyses that are still to come.